The OSU Carlson College of Veterinary Medicine offers clinical trials of new treatments and procedures in a variety of areas including oncology, cardiology, orthopedic surgery, and more. These trials will help to develop future treatments and diagnostic tools that are both safe and effective.

Answers to frequently asked questions about clinical trials can be found here. For information about a specific trial, please contact the individual at the bottom of each trial summary below. 

The following are current, open clinical trials that are seeking participants.

ONCOLOGY

The hospital is a member of the Comparative Oncology Trials Consortium (COTC), a network of twenty academic oncology centers, centrally managed by the National Institute of Health, that design and conduct clinical trials in dogs with cancer in order to assess new therapies. 

Investigation of Listeria Vaccine for Osteosarcoma in Dogs

Evaluation of a recombinant, attenuated Listeria monocytogenes expressing a chimeric human HER2/neu protein in dogs with osteosarcoma in the adjuvant setting. Purpose:

  • To investigate the effectiveness of a Listeria vaccine (ADXS31-164) in delaying or preventing metastatic disease in dogs with osteosarcoma treated with standard of care therapy (amputation and carboplatin).  
  • Evaluate the effects of the vaccine in the setting of established metastatic disease from osteosarcoma.

The study is enrolling newly diagnosed dogs (no prior therapy for osteosarcoma such as chemotherapy, radiation, bisphosphonates) with the following criteria: Confirmed appendicular osteosarcoma with measurable disease of the radius, humerus, ulna, femur or tibia that is amenable to surgical removal via amputation; no evidence of metastasis based on physical exam, thoracic radiographs and abdominal ultrasound; patient is otherwise heatlhy and weighs greater than 28 kg.

Once the patient is enrolled in the trial, recheck exams and other serviceable fees will be at a reduced cost.  Most costs associated with the ADXS31-164 vaccination will be covered by the study, and the vaccine itself will be at no cost.  In the event that complications arise from the administration of ADXS31-164 to the patient, the study will cover the cost of complication treatment up to $500 per patient.  Owner is responsible for costs of initial diagnostics to confirm enrollment (~$1,000-1,200), and the cost of amputation (~$2,500-3,500) and carboplatin chemotherapy (approximately $2,000-3,000 after service discounts). Owners will be responsible for payment of all other veterinary costs related to the care and treatment of their pets.  

Please do not hesitate to contact the OSU Oncology Service with any questions: Drs. Katie Curran, Shay Bracha, and Cyril Parachini-Winter are available at the main hospital number: (541) 737-4812. 

Canine Mammary Tumor Study

The objective of this clinical trial is to evaluate the toxicity and safety of the SiNc-NP nanoparticle when given to dogs with mammary tumors prior to resection of their mass. OSU’s Carlson College of Veterinary Medicine and College of Pharmacy is developing a novel nanoplatform imaging modality that allows real-time intra-operative visualization of tumor extent to help guide resection. The examined nanoparticle has shown to accumulate within tumor cells in a mouse model that allowed an easier surgical removal of the mass in addition to activation under exposure to a laser light which induces the death of non resectable cancer cells. After surgery, patients will be scheduled for a 2-week post-operative recheck for incision healing at which will mark the end of the clinical trial for the patient. 

The study is enrolling female canines who have been spayed 2 years prior to diagnoseswith cytologically-confirmed mammary neoplasia and mass diameter of 1-7cm. This trial requires a CT of abdomen and thorax to confirm no evidence of pulmonary  metastatic disease. The patient must not have had surgical excision or radiation treatment of mass, concurrent malignancy or other serious systemic disorder incompatible with this study. There is no weight requirement associated with this trial. 

VTH credit in the amount of $4,500.00 will be applied to patients account as part of trial participation.  Any expense beyond this amount will be billed to the owner and will be their responsibility to cover, including the cost of surgery, and any unanticipated hospitalizations. 

Please do not hesitate to contact the OSU Oncology Service with any questions: Dr. Katie Curran, Shay Bracha, and Haley Leeper are available at the main hospital number: (541) 737-4812.

Canine Patients with Naïve Multi-centric Lymphoma

Sulforaphane (SFN) is a natural compound found in cruciferous vegetables such as broccoli.  Sulforaphane has been shown to play a powerful role in tumor suppression.  This study will investigate SFN supplementation in dogs with lymphoma.  Specifically, we will evaluate the bioavailability and epigenetic activity of SFN to assess it as a potential tumor suppressing agent in dogs with lymphoma. 

The qualifying patient must have cytologic or histologic confirmation of lymphoma, clinically healthy (sub-stage a). Patient must weigh greater than 15kgs. Prior/concurrent therapy is not permitted. 

Client will receive discounted services and $1,000 to $1,500 VTH credit once trial is completed.

Please do not hesitate to contact the OSU Oncology Service with any questions: Dr. Katie Curran, Shay Bracha, and Haley Leeper are available at the main hospital number: (541) 737-4812.

Clinical Trial: The Effect of Short-term Fasting on Immune Surveillance in Normal and Osteosarcoma Bearing Dogs. 

Fasting cycles have been shown in several models to provide both promotion of malignant cell death and protective benefits to normal cells when exposed to chemotherapy. Dogs diagnosed with either Axial or Appendicular osteosarcoma will be eligible for enrollment. All enrolled patients will have pre-fasting blood samples taken the morning of Day 0.  Patients will then be fasted for 24-hours (with water available at all times).  The morning of Day 1 (24-hours later), patient will again have a blood sample obtained to conclude the study. 

The qualifying patient must weigh greater than 10kg. Prior/concurrent therapy is not permitted. 

Upon trial completion a $150 credit  will be applied to the client’s bill at the OSU Veterinary Teaching Hospital for compensation for participating. 

Clinical Trial: T lymphocyte population patterns in canine osteosarcoma patients on cytotoxic chemotherapy. 

OSA with planned amputation as primary therapy and standard of care (carboplatin) chemotherapy to follow. No weight requirement. Prior/concurrent therapy is not permitted. 

There is no financial incentive for participation. The benefit of this study is to provide samples (extra blood) for research. 

Please do not hesitate to contact the OSU Oncology Service with any questions: Dr. Katie Curran, Shay Bracha, and Haley Leeper are available at the main hospital number: (541) 737-4812. 

Canine OSA, LSA or other malignancy suitable for Carboplatin or Vincristine Study

Evaluation of Fasting in Mitigation of Vincristine and Carboplatin Chemotherapy Associated Side Effects in Cancer-Bearing Dogs. 

LSA, OSA or other malignancy suitable for Vincristine or Carboplatin therapy. Patient must weigh greater than 10kg and MDR-1 status of normal/normal. Prior/concurrent therapy is not permitted. 

Participants will recieve discounted exam fees and other serviceable fees. Trial related CBC and Glucose laboratory testing is at no cost to client. 

Please do not hesitate to contact the OSU Oncology Service with any questions: Dr. Katie Curran, Shay Bracha, and Haley Leeper are available at the main hospital number: (541) 737-4812. 

Canine Urogenital Carcinoma Study

Patients with confirmed urogenital carcinoma of the urinary bladder, urethra or prostate via cytology or histopathology. 

Patient must weigh greater than 5 kgs. Prior/concurrent therapy is not permitted with the exception of NSAIDS. 

Participants will receive discounted physical exams, serviceable fees and $100.00 VTH credit to apply towards restaging appointments (up to 4 apt). 

Please do not hesitate to contact the OSU Oncology Service with any questions: Dr. Katie Curran, Shay Bracha, and Haley Leeper are available at the main hospital number: (541) 737-4812. 

Canine Histiocytic Sarcoma Study

Histiocytic sarcoma (HS) is a relatively uncommon malignant form of cancer that has a poor response to therapy. The purpose of this study is to evaluate the safety and efficacy of a new chemotherapy protocol for the treatment of naïve canine HS patients. Patients enrolled in this clinical trial will receive a new combination protocol (lomustine alternating with doxorubicin + zoledronate).

Patients must have confirmed histiocytic sarcoma (localized, disseminated or hemophagocytic) based on cytology with ICC or histopathology with IHC. They must weigh greater than 15kgs. No prior/concurrent therapy permitted. 

Compensation for participation in this clinical trial includes discounted exams fees and other serviceable fees. Questions? Please contact Dr. Katie Curran or Dr. Shay Bracha: 541-737-4812. 

 

SOFT TISSUE SURGERY

Canine Transitional Cell Carcinoma Study

We are recruiting dogs with non-trigonal urinary bladder tumors (e.g. mass at the apex or mid-body of the bladder) for a novel surgical method that allows partial cystectomy while minimizing risk for tumor cell “seeding” into the abdominal cavity and/or body wall during surgery. More detailed information.

  • What does the study involve? Exam and consultation one day, anesthesia with cystoscopy and partial cystectomy to remove the affected portion of the urinary bladder the next day; dogs typically discharged 1 day postop.
  • Who may qualify for the study? Client-owned dogs with a bladder mass not involving the trigone.
  • Exclusion criteria: previous bladder surgery for the tumor in question (historical cystotomy for stones or other non-neoplastic disease is OK)
  • Client incentives: Financial discounts ranging from $500-700 per dog (Total final expected client bill of $2-3000 depending on duration of procedure)

If you have a dog owner interested in participating, please have them schedule an appointment with the Soft Tissue Surgery Service at 541-737-4812.

Questions? Please contact Dr. Milan Milovancev (milan.milovancev@oregonstate.edu; 541-737-3527) or Dr. Jana Gordon (jana.gordon@oregonstate.edu; 541-737-4808). 

 

CARDIOLOGY

Subaortic Stenosis Study

Dogs with subaortic stenosis are at increased risk for sudden death, and the benefits of standard therapy with Atenolol are unclear. The OSU Cardiology service is performing a study comparing the short-term effects of Atenolol and Sotalol on ventricular function, heart rate, and arrhythmias. We are recruiting young dogs with left basilar systolic murmurs for evaluation. Research funding supports much of the expense (~$650). Eligible dogs and owners are expected to pay exam fees (~$15 per visit). Study participants will be evaluated at 0, 2, and 5 weeks.

Questions? Please contact Dr. Katherine Scollan or Dr. Nicole LeBlanc: 541-737-4812.

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Study

Dogs with ARVC are at increased risk for sudden death, and some also develop systolic dysfunction which may progress to congestive heart failure. Sotalol is commonly used to treat arrhythmias in dogs with ARVC. However, the inotropic effects of sotalol have not been well-evaluated in dogs, and a reduction in contractility could precipitate heart failure in dogs affected with systolic dysfunction. The OSU Cardiology is performing a study evaluating the effects of Sotalol on systolic function in normal dogs and dogs with ARVC. We are recruiting adult Boxers (>4 years of age or with a clinical suspicion of arrhythmias) for screening for ARVC. Dogs who meet the criteria for ARVC on initial Holter monitor, and without echocardiographic evidence of overt left or right ventricular dysfunction, will be enrolled. Research funding supports much of the expense (~$265). Owners are expected to pay for Holter monitoring (~$300 x2) to establish the diagnosis and evaluate the response to anti-arrhythmic therapy. Study participants will be evaluated at 0 and 2 weeks.

Questions? Please contact Dr. Katherine Scollan or Dr. Nicole LeBlanc: 541-737-4812. 

 

LARGE ANIMAL MEDICINE

Colloid transfusion in horses with gastrointestinal disease

Description: We are evaluating the impact of plasma and hetastarch transfusion on colloid osmotic pressure and specific biochemical and hematologic variables in horses with naturally occurring gastrointestinal disease that receive transfusions in the course of normal treatment. Costs of testing are covered in the trial and results are provided to clinicians and owners to help direct therapies and monitor progress in patients.

Contact: Dr. Erica McKenzie at 541-737-4809 or at erica.mckenzie@oregonstate.edu

 

Recently Completed Clinical Trials

Vitamin E and selenium supplementation practices in Pacific Northwestern horses

Canine Laryngeal Paralysis Study

Feline Hyperthyroidism Study
A study on CT imaging of the thyroid in awake cats. Completed June 2014. Abstract.

Feline Injection Site Sarcoma Study
A study of cats affected by, or suspected to be affected by, an injection site sarcoma. Completed June 2014. Abstract.

Platelet-Rich Plasma (PRP) Injection for Dogs with Hip Osteoarthritis

Giant Breed Growth Plate Study
Evaluation of bone development in large and giant breed dogs. Abstract.

Canine Osterosarcoma Study
Clinical trials for dogs with appendicular osteosarcoma.

 

All clinical trials in the Lois Bates Acheson Veterinary Teaching Hospital undergo prior review and approval by IACUC.